Raju Mohan joined New Science Ventures in 2017 as a Senior Advisor to the firm. He has over 25 years of drug discovery and development experience in pharma and biotech. Raju has co-founded multiple biotech companies, including Akarna Therapeutics (acquired by Allergan), Ralexar Therapeutics, Escalier Biosciences and Oppilan Pharma. Raju founded and served as President of Anayaderm (acquired by Ralexar) and has previously served as the Vice President of Chemistry at X-Ceptor (acquired by Exelixis) and Vice-President and site-head for Exelixis’ San Diego site. He has also held increasingly senior positions at Berlex Biosciences, a subsidiary of Bayer/Schering AG. Raju is responsible for the discovery of multiple small-molecule compounds that have entered the clinic including one currently in Phase 3 trials. He has published extensively in peer-reviewed journals and is an inventor on 50 issued US patents. Raju received his Ph.D. in Chemistry from the University of Illinois at Urbana-Champaign and his Master’s degree from the Indian Institute of Technology.